Artificial Intelligence to Personalize Prostate Cancer Treatment (the HypoElect Trial)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE2

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-09-16

Study Completion Date

2027-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A prospective, single-arm phase II study is the individualization of RT for patients with high-risk localized PCa based on multimodal artificial intelligence (MMAI). All patients will receive the current standard of care: (i) a dose escalation to the prostate via HDR brachytherapy, (ii) two years of ADT and (iii) whole-pelvis UHF-RT (5 fractions).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Artificial Intelligence Driven Personalisation of Radiotherapy and Concomitant Androgen Deprivation Therapy for Prostate Cancer Patients (the HypoPro Trial)

NCT06772441

Prostate Cancer

RECRUITING PHASE2

Hypo-Combi Trial: Hypofractionated EBRT Plus HDR-BT Boost for Prostate Cancer

NCT05003752

Prostate Adenocarcinoma Radiation Toxicity

ACTIVE_NOT_RECRUITING PHASE1/PHASE2

Leuprolide Acetate or Goserelin Acetate With or Without Vismodegib Followed by Surgery in Treating Patients With Locally Advanced Prostate Cancer

NCT01163084

Prostate Adenocarcinoma Stage IIA Prostate Cancer AJCC v7 Stage IIB Prostate Cancer AJCC v7

TERMINATED PHASE1/PHASE2

Study on the Role of Hormonal Treatment for Two Dosage Levels of Prostate Radiation Therapy Versus Prostate Radiation Therapy Alone

NCT00223145

Prostate Cancer

ACTIVE_NOT_RECRUITING PHASE3

Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma

NCT03436654

Prostate Cancer

ACTIVE_NOT_RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Prostate cancer (PCa) is the most frequent diagnosed malignancy in male patients in Europe and radiation therapy (RT) is a main treatment option. For primary high-risk localized PCa patients, NCCNv4.2023 guidelines recommend normo- or hypofractionated RT to the prostate ± the elective pelvic lymphatics and systemic treatment in terms of ADT. Although the standard of care, the benefit of this therapy regimen is controversially discussed: the benefit of (i) an RT dose escalation using brachytherapy (2) or focal dose escalated RT(3) or (ii) an elective RT of the pelvic lymph nodes (1) is not finally proven yet. In parallel, first studies proposed a reduction in treatment fractions in terms of ultra-hypofractionated RT (UHF-RT) (4).

The aim of this prospective, single-arm phase II study is the individualization of RT for patients with high-risk localized PCa based on MMAI. All patients will receive the current standard of care: (i) a dose escalation to the prostate via HDR brachytherapy, (ii) two years of ADT and (iii) whole-pelvis UHF-RT (5 fractions).

For the HypoElect patients we expect no significant differences in toxicity rates compared to the randomized controlled POP-RT trial (1) which treated the patients with moderately-hypofractionated RT to the prostate and the elective pelvic lymph nodes in parallel to 24 months of ADT. Secondary endpoints like relapse free survival, metastatic free survival, prostate cancer survival and overall survival will depict the oncologic efficacy in this patient cohort. Thus, the safety and oncologic outcome results of this study might be the first in this highly selected treatment group: NCCN high-risk, PSMA PET cN0/cM0 and MMAI high-risk. Considering the epidemiological importance of the PCa these results could have a significant socio-economic impact. In parallel a translational research program will address the identification of novel biomarkers to predict the treatment outcome.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Prostate Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Single experimental arm

RT prostate (HDR brachytherapy): 15 Gy (D90) in 1 fraction HDR RT prostate

EBRT elective pelvis (Ultra-hypofractionated RT - UHF): 25 Gy in 5 Gy per fraction

Technique: IMRT/IGRT/HDR brachytherapy

Duration: 6 fractions, 3 weeks

Androgen deprivation therapy (ADT) - Goserelin: all patients receive ADT; luteinising-hormone-releasing hormone agonists or antagonists for 24 months

Follow-up (FU) per patient: minimum FU time is 5 years (60 months), the study ends when the last enrolled patients reaches 60 months of FU time

Further FU: by the end of this clinical trial it will be decided whether further FU is necessary, amendment to this clinical trial protocol will be done in appropriate time

Group Type EXPERIMENTAL

Androgen Deprivation Therapy (ADT) - Goserelin

Intervention Type DRUG

The patients under ADT and the patients who will receive the ADT during the study will be included in the trial.

* ADT will be applied for 24 months in total
* ADT must be given concurrently and adjuvant

High-Dose-Rate Interstitial Brachytherapy (HDR BRT)

Intervention Type RADIATION

HDR BRT Procedure will be performed using transperineal catheter implantation under transrectal US-guidance performed under anesthesia, spinal or general with patient in high lithotomy position.)

radiotherapy

Intervention Type RADIATION

EBRT prostate + elective pelvis (Ultra-hypofractionated): 25 Gy in 5 Gy per fraction

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Androgen Deprivation Therapy (ADT) - Goserelin

The patients under ADT and the patients who will receive the ADT during the study will be included in the trial.

* ADT will be applied for 24 months in total
* ADT must be given concurrently and adjuvant

Intervention Type DRUG

High-Dose-Rate Interstitial Brachytherapy (HDR BRT)

HDR BRT Procedure will be performed using transperineal catheter implantation under transrectal US-guidance performed under anesthesia, spinal or general with patient in high lithotomy position.)

Intervention Type RADIATION

radiotherapy

EBRT prostate + elective pelvis (Ultra-hypofractionated): 25 Gy in 5 Gy per fraction

Intervention Type RADIATION

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically confirmed adenocarcinoma of the prostate (histological confirmation can be based on tissue taken at any time, but a re-biopsy should be considered if the biopsy is more than 12 months old)
* Primary PCa (in PSMA-PET imaging and multiparametric magnetic resonance imaging (mpMRI)
* High- or very high-risk according to NCCNv1.2023 criteria
* Signed written informed consent for this study
* Age \>18 years
* Previously conducted PSMA-PET/CT, mpMRI or PSMA-PET/MR
* MMAI high-risk
* ECOG Performance score 0 or 1
* IPSS Score ≤15

Exclusion Criteria

* Prior radiotherapy to the prostate or pelvis
* Prior radical prostatectomy
* Prior focal therapy approaches to the prostate
* Evidence of pelvic nodal disease (cN+) in mpMRI and/or PSMA-PET/CT
* Evidence of distant metastatic disease (cM+) in mpMRI and/or PSMA-PET/CT
* Time gap between the beginning of any systemic therapyADT and conduction of PSMA-PET scans is \>2 months
* Evidence of cT4 disease in mpMRI and/or PSMA-PET/CT
* PSA \>50 ng/ml prior to starting of systemic therapy
* Expected patient survival \<5 years
* Bilateral hip prostheses or any other implants/hardware that would introduce substantial CT artifacts
* Contraindication to undergo a MRI scan
* Contraindication to undergo HDR brachytherapy (brachytherapy not feasible due to large prostate volume, prostate anatomy, tumor in distant seminal vesicles and/or unfit for anesthesia)
* Prostate surgery (TURP or HOLEP) with a significant tissue cavity or prostate surgery (TURP or HOLEP) within the last 6 months prior to randomization
* Medical conditions likely to make radiotherapy inadvisable e.g. acute inflammatory bowel disease, hemiplegia or paraplegia
* Previous malignancy within the last 2 years (except basal cell carcinoma or squamous cell carcinoma of the skin), or if previous malignancy is expected to significantly compromise 5 year survival
* Any other contraindication to external beam radiotherapy (EBRT) to the pelvis
* Participation in any other interventional clinical trial within the last 30 days before the start of this trial
* Simultaneous participation in other interventional trials which could interfere with this trial; simultaneous participation in registry and diagnostic trials is allowed
* Patient without legal capacity who is unable to understand the nature, significance and consequences of the trial
* Known or persistent abuse of medication, drugs or alcohol

Minimum Eligible Age

18 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No